登革病毒感染12年后抗体阳性情况调查

doi:10.11853/j.issn.1003.8280.2023.05.016

摘要/Abstract

摘要： 目的调查登革病毒感染12年后不同特征人群IgG抗体阳性情况,为预防重症登革热提供科学依据。方法2021年10月采集2009年浙江省义乌市登革热暴发时的病例和无症状感染者血清样本,采用间接酶联免疫吸附试验（ELISA）检测样本中登革病毒IgG抗体,计算不同特征人群的IgG抗体阳性率,采用卡方检验分析不同特征调查对象血清阳性率差异,采用logistic回归多因素分析,分析抗体阳性的相关影响因素；用R 4.2.1软件进行统计学分析。结果共采集登革病毒既往感染者标本123份,登革病毒IgG抗体阳性101份,总阳性率为82.11%。采集对象中无症状感染者57例,阳性率为64.91%（37/57）；登革热病例66例,阳性率为96.97%（64/66）；病例样本的阳性率显著高于无症状感染者（χ²=21.401,P<0.001）。调查男性41例,阳性率为85.37%（35/41）；女性82例,阳性率为80.49%（66/82）。共调查2009年感染登革病毒时年龄≤40岁的感染者14例,登革病毒IgG抗体阳性12例；41～60岁的58例,阳性率为81.03%（47/58）；≥61岁的51例,阳性率为82.35%（42/51）。Logistic回归分析结果显示,登革病毒感染者类型与抗体是否阳性显著相关,相对于无症状感染者标本,病例标本抗体阳性的比值比（OR）为17.30（95%置信区间：3.83～78.21）。结论登革病毒感染12年后IgG抗体阳性率仍然较高,且病例样本的阳性率显著高于无症状感染者,这些既往感染者一旦二次感染登革病毒,发生重症登革热的风险较高。

关键词: 登革病毒, IgG抗体, 二次感染, 重症病例

Abstract: Objective To investigate the seroprevalence of IgG antibodies among individuals with different characteristics 12 years after Dengue virus infection, so as to provide a scientific basis for the prevention of severe dengue fever.Methods In October 2021, serum samples were collected from symptomatic and asymptomatic cases in the 2009 dengue outbreak in Yiwu, Zhejiang Province, China. IgG antibodies to Dengue virus in the samples were measured using indirect enzyme-linked immunosorbent assay. The positive rates of IgG antibodies in populations with different characteristics were calculated and compared using the Chi-squared test. Multivariable logistic regression analysis was used to analyze the factors affecting the positive rate of the antibodies. R 4.2.1 was used for statistical analysis.Results A total of 123 samples were collected from individuals infected with Dengue virus in the outbreak, of which 101 samples were positive for dengue virus-specific IgG antibodies, with a positive rate of 82.11%. Among the investigated individuals, 57 were asymptomatic cases, with a positive rate of 64.91% (37/57), and 66 were symptomatic cases, with a positive rate of 96.97% (64/66). The positive rate of the symptomatic cases was significantly higher than that of the asymptomatic cases (χ²=21.401, P<0.001). There were 41 male and 82 female participants, with the positive rates being 85.37% (35/41) and 80.49% (66/82), respectively. Fourteen cases were ≤40 years old when they infected with Dengue virus in 2009, with 12 cases were positive; 58 cases were aged 41-60 years, with a positive rate of 81.03% (47/58); and 51 cases were ≥60 years old, with a positive rate of 82.35% (42/51). The logistic regression analysis showed a significant association between the type of infected individuals and the presence of the antibodies. The odds ratio of antibody positivity of symptomatic cases relative to asymptomatic cases was 17.30 (95% confidence interval: 3.83-78.21).Conclusions The positive rate of the IgG antibodies was still high 12 years after Dengue virus infection, which was significantly higher in symptomatic cases than in asymptomatic cases. Individuals with past Dengue virus infection have a high risk of being severe once they are re-infected.

Key words: Dengue virus, IgG antibody, Second infection, Severe case

中图分类号:

R373.3⁺3

陈劲华, 骆淑英, 刘营, 凌锋, 孙继民. 登革病毒感染12年后抗体阳性情况调查[J]. 中国媒介生物学及控制杂志, 2023, 34(5): 679-681.

CHEN Jin-hua, LUO Shu-ying, LIU Ying, LING Feng, SUN Ji-min. Seroprevalence of dengue-specific IgG antibodies 12 years after Dengue virus infection[J]. Chinese Journal of Vector Biology and Control, 2023, 34(5): 679-681.

参考文献

[1] World Health Organization. Dengue guidelines,for diagnosis,treatment,prevention and control[R]. Geneva:World Health Organization,2009:14.
[2] Bhatt S,Gething PW,Brady OJ,et al. The global distribution and burden of dengue[J]. Nature,2013,496（7446）:504-507. DOI:10.1038/nature12060.
[3] World Health Organization. Dengue and severe dengue[EB/OL]. （2023-03-17）[2023-03-17]. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
[4] Brady OJ,Gething PW,Bhatt S,et al. Refining the global spatial limits of Dengue virus transmission by evidence-based consensus[J]. PLoS Negl Trop Dis,2012,6（8）:e1760. DOI:10.1371/journal.pntd.0001760.
[5] Liu QY. Dengue fever in China:New epidemical trend,challenges and strategies for prevention and control[J]. Chin J Vector Biol Control,2020,31（1）:1-6. DOI:10.11853/j.issn.1003.8280.2020.01.001.（in Chinese）刘起勇. 我国登革热流行新趋势、防控挑战及策略分析[J]. 中国媒介生物学及控制杂志,2020,31（1）:1-6. DOI:10.11853/j.issn.1003.8280.2020.01.001.
[6] Wang Z,Ling F,Liu Y,et al. Epidemiological characteristics of dengue fever in Zhejiang province,China,2015-2019[J]. Chin J Vector Biol Control,2020,31（6）:643-647. DOI:10.11853/j.issn.1003.8280.2020.06.003.（in Chinese）王桢,凌锋,刘营,等. 浙江省2015－2019年登革热流行特征分析[J]. 中国媒介生物学及控制杂志,2020,31（6）:643-647. DOI:10.11853/j.issn.1003.8280.2020.06.003.
[7] Ren JP,Chen ZP,Ling F,et al. Epidemiology of indigenous dengue cases in Zhejiang province,Southeast China[J]. Front Public Health,2022,10:857911. DOI:10.3389/fpubh.2022. 857911.
[8] Sun JM,Lin JF,Yan JY,et al. Dengue virus serotype 3 subtype III,Zhejiang province,China[J]. Emerg Infect Dis,2011,17（2）:321-323. DOI:10.3201/eid1702.100396.
[9] Lau L,Green AM,Balmaseda A,et al. Antibody avidity following secondary Dengue virus type 2 infection across a range of disease severity[J]. J Clin Virol,2015,69:63-67. DOI:10.1016/j.jcv.2015.06.003.
[10] Dejnirattisai W,Jumnainsong A,Onsirisakul N,et al. Cross-reacting antibodies enhance Dengue virus infection in humans[J]. Science,2010,328（5979）:745-748. DOI:10.1126/science. 1185181.
[11] de Alwis R,Williams KL,Schmid MA,et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera[J]. PLoS Pathog,2014,10（10）:e1004386. DOI:10.1371/journal.ppat.1004386.
[12] Guzman MG,Alvarez M,Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome:An historical perspective and role of antibody-dependent enhancement of infection[J]. Arch Virol,2013,158（7）:1445-1459. DOI:10.1007/s00705-013-1645-3.
[13] Imrie A,Meeks J,Gurary A,et al. Antibody to Dengue 1 detected more than 60 years after infection[J]. Viral Immunol,2007,20（4）:672-675. DOI:10.1089/vim.2007.0050.
[14] Ngwe Tun MM,Muta Y,Inoue S,et al. Persistence of neutralizing antibody against Dengue virus 2 after 70 years from infection in Nagasaki[J]. Biores Open Access,2016,5（1）:188-191. DOI:10.1089/biores.2016.0016.
[15] WuQL. Kinetics of antibodies in patients with dengue and analysis of dengue antibody levels in healthy population in Guangzhou[D]. Guangzhou:Guangdong Pharmaceutical University,2020. （in Chinese）吴琦琳. 登革热病例抗体动力学及广州市健康人群登革热抗体水平分析[D]. 广州:广东药科大学,2020.
[16] Ma YS,Li M,Xie L,et al. Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong,Yunnan[J]. Virol Sin,2022,37（1）:19-29. DOI:10.1016/j.virs.2021. 12.001.
[17] Luo SY,Cui WH,Li C,et al. Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang province,China[J]. BMC Infect Dis,2018,18（1）:92. DOI:10.1186/s12879-018-3000-5.
[18] Luo SY,Liu Y,Fu T,et al. An investigation of seroprevalence of IgG antibodies in infected cases nine years after a dengue outbreak[J]. Chin J Vector Biol Control,2019,30（4）:371-373. DOI:10.11853/j.issn.1003.8280.2019.04.003.（in Chinese）骆淑英,刘营,傅涛,等. 登革热暴发9年后感染者抗体阳性率调查[J]. 中国媒介生物学及控制杂志,2019,30（4）:371-373. DOI:10.11853/j.issn.1003.8280.2019.04.003.
[19] Sun JM,Luo SY,Lin JF,et al. Inapparent infection during an outbreak of dengue fever in Southeastern China[J]. Viral Immunol,2012,25（6）:456-460. DOI:10.1089/vim.2012.0039.